Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.2.1.23 (
beta-galactosidase
)
14,648
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
5-Aminolevulinic acid (
ALA
) is a heme precursor that accumulates in some porphyric disorders and in lead poisoning which can undergo metal-catalyzed oxidation producing reactive oxygen species and the keto-aldehyde, 4,5-dioxovaleric acid (DOVA). Evidence in vitro of
ALA
-induced DNA lesions suggests that
ALA
and DOVA have mutagenic potential that could possibly contribute to an increased frequency of hepatocellular carcinoma (HCC) in patients with acute intermittent porphyria (AIP). In this study, we evaluated the genotoxic potential of
ALA
and DOVA. In the absence of exogenous metabolic activation,
ALA
and DOVA were mutagenic in Salmonella typhimurium tester strain TA104.
ALA
was also mutagenic in S. typhimurium TA102, but not in TA98, TA100, or TA1535, indicating an oxidative mechanism. Removal of H(2)O(2) with catalase gave only partial protection, suggesting generation of other mutagenic species. Both
ALA
and DOVA damaged the DNA of Escherichia coli PQ37, inducing the SOS response detected by an increase in
beta-galactosidase
activity. These results verified the potential mutagenic activity of
ALA
and DOVA and reinforce the hypothesis that DNA damage induced by
ALA
may be associated with the development of HCC in individuals suffering from AIP.
...
PMID:Genotoxicity of 5-aminolevulinic and 4,5-dioxovaleric acids in the salmonella/microsuspension mutagenicity assay and SOS chromotest. 1221 Oct 78
